```
A@ 1
                                                          16 1
chain nodes :
  7 9 10 18 19 20 27 29
ring nodes :
   1 2 3 4 5 6 11 12 13 14 15 16
ring/chain nodes :
   8
chain bonds :
   2-7 4-27 5-9 6-10 7-13 8-9 9-29
ring bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
   2-7 4-27 7-13 8-9 9-29
exact bonds :
   5-9 6-10
normalized bonds :
   1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
   containing 1 : 11 :
G1:Cl,Br,F,I,[*1],[*2],[*3]
G2:H,[*1]
Match level :
   1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:Atom
   12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:Atom 20:Atom 27:CLASS 29:CLASS
Generic attributes :
   18:
```

C:\Program Files\Stnexp\Queries\10597521 (a).str

Saturation

20:

: Saturated

: Saturated

Number of Carbon Atoms : less than 7

Number of Carbon Atoms : less than 7

Saturation : Saturated Number of Carbon Atoms : less than 7

Element Count : Node 18: Limited C,C1-6

Node 19: Limited C,C1-6

=>

Uploading C:\Program Files\Stnexp\Queries\10597521.str

```
chain nodes :
7 9 10 18 19 20 27
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
ring/chain nodes :
chain bonds :
2-7 4-27 5-9 6-10 7-13 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-7 4-27 7-13 8-9
exact bonds :
5-9 6-10
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 11-12 \quad 11-16 \quad 12-13 \quad 13-14 \quad 14-15 \quad 15-16
isolated ring systems :
containing 1: 11:
```

```
G1:C1, Br, F, I, [*1], [*2], [*3]
Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:Atom 20:Atom
Generic attributes :
Saturation
                    : Saturated
Number of Carbon Atoms : less than 7
                    : Saturated
Saturation
Number of Carbon Atoms : less than 7
20:
Saturation
                     : Saturated
Number of Carbon Atoms : less than 7
Element Count :
Node 18: Limited
   C,C1-6
Node 19: Limited
  C,C1-6
L1 STRUCTURE UPLOADED
=> d 11
L1 HAS NO ANSWERS
              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
Structure attributes must be viewed using STN Express query preparation.
=> s 11 sss sam
SAMPLE SEARCH INITIATED 18:14:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 478 TO ITERATE
100.0% PROCESSED 478 ITERATIONS
                                                             33 ANSWERS
SEARCH TIME: 00.00.01
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                       BATCH **COMPLETE**
PROJECTED ITERATIONS:
                           8249 TO 10871
                             315 TO
PROJECTED ANSWERS:
                                      1003
            33 SEA SSS SAM L1
=> =>
Uploading C:\Program Files\Stnexp\Queries\10597521 (a).str
```



```
chain nodes :
7 9 10 18 19 20 27 29
ring nodes :
1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 11 \quad 12 \quad 13 \quad 14 \quad 15 \quad 16
ring/chain nodes :
chain bonds :
2-7 4-27 5-9 6-10 7-13 8-9 9-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-7 4-27 7-13 8-9 9-29
exact bonds :
5-9 6-10
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 11-12 \quad 11-16 \quad 12-13 \quad 13-14 \quad 14-15 \quad 15-16
isolated ring systems :
containing 1 : 11 :
```

G1:C1, Br, F, I, [\*1], [\*2], [\*3] G2:H,[\*1] Match level: 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:Atom 20:Atom 27:CLASS 29:CLASS Generic attributes : 18: : Saturated Saturation Number of Carbon Atoms : less than 7 : Saturated Saturation Number of Carbon Atoms : less than 7 : Saturated Saturation Number of Carbon Atoms : less than 7 Element Count : Node 18: Limited C,C1-6 Node 19: Limited C,C1-6 L3 STRUCTURE UPLOADED => d 13L3 HAS NO ANSWERS \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* Structure attributes must be viewed using STN Express query preparation. => s 13 sss sam SAMPLE SEARCH INITIATED 18:17:30 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 478 TO ITERATE 100.0% PROCESSED 478 ITERATIONS 8 ANSWERS SEARCH TIME: 00.00.01 FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*
BATCH \*\*COMPLETE\*\* PROJECTED ITERATIONS: 8249 TO 10871 PROJECTED ANSWERS: 8 TO

8 SEA SSS SAM L3

L4

=> => s 13 sss ful

FULL SEARCH INITIATED 18:18:07 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10491 TO ITERATE

100.0% PROCESSED 10491 ITERATIONS

184 ANSWERS

SEARCH TIME: 00.00.01

L5 184 SEA SSS FUL L3

=> => s 15

L6 2 L5

 $\Rightarrow$  d 16 1-2 bib,ab,hitstr

```
L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
```

AN 2007:201033 CAPLUS

DN 146:274347

- TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
- IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
- PA Anormed Inc., Can.
- SO PCT Int. Appl., 363pp. CODEN: PIXXD2
- DT Patent
- LA English

FAN.CNT 1

PA	TENT :	NO.			KIN	D	DATE		****	APPL	ICAT		DATE						
			. –			,									20060816				
	₩:	CN, GE, KR,	CO, GH, KZ,	CR, GM, LA,	CU, HN, LC,	CZ, HR, LK,	DE, HU, LR,	DK, ID, LS,	DM, IL, LT,	DZ, IN, LU,	EC, IS, LV,	EE, JP, LY,	EG, KE, MA,	ES, KG, MD,	FI, KM, MG,	GB, KN, MK,	GD, KP, MN,		
		RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,										
	R₩:	IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,		
												UG,	ZM,	ZW,	AM,	AZ,	BY,		
CA	2619	881			A1	A1 20070222 CA 2006-2619881									20060816				
US	2007	624		A1 20070322 US 2006-505669								20060816							
ΕP	1924						EP 2006-813506						20060816						
	R:	IS,	IT,	LI,	LT,			•											
IN	2008	KN00	797		A 20081121 IN 2008-KN797								20080222						
US WO	2005 2006	P W		2005	0816		J11 2												
	CA US EP IN CN US WO	WO 2007 WO 2007 W:  RW:  CA 2619 US 2007 EP 1924 R:  JP 2009 IN 2008 CN 1013 US 2005 WO 2006	WO 20070223 W: AE, CN, GE, KR, MW, RU, UG, RW: AT, IS, CF, GM, KG, CA 2619881 US 20070066 EP 1924265 R: AT, IS, BA, JP 20095047 IN 2008KN00 CN 10130969 US 2005-708 WO 2006-US3	WO 2007022371 WO 2007022371 W: AE, AG, CN, CO, GE, GH, KR, KZ, MW, MX, RU, SC, UG, US, RW: AT, BE, IS, IT, CF, CG, GM, KE, KG, KZ, CA 2619881 US 20070066624 EP 1924265 R: AT, BE, IS, IT, BA, HR, JP 2009504769 IN 2008KN00797 CN 101309690 US 2005-708471P WO 2006-US32170	WO 2007022371 WO 2007022371 W: AE, AG, AL,	WO 2007022371 A2 WO 2007022371 A3 W: AE, AG, AL, AM,	WO 2007022371 A2 WO 2007022371 A3 W: AE, AG, AL, AM, AT, CN, CO, CR, CU, CZ, GE, GH, GM, HN, HR, KR, KZ, LA, LC, LK, MW, MX, MY, MZ, NA, RU, SC, SD, SE, SG, UG, US, UZ, VC, VN, RW: AT, BE, BG, CH, CY, IS, IT, LT, LU, LV, CF, CG, CI, CM, GA, GM, KE, LS, MW, MZ, KG, KZ, MD, RU, TJ, CA 2619881 A1 US 20070066624 A1 EP 1924265 A2 EP 1924265 A2 EP 1924265 A2 EP 1924265 T, IT, LI, LT, LU, BA, HR, MK, RS JP 2009504769 T IN 2008KN00797 A CN 101309690 A US 2005-708471P WO 2006-US32170 W	WO 2007022371	WO 2007022371 WO 2007022371 WS: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, UG, US, UZ, VC, VN, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, CG, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  CA 2619881 A1 20070222 CA 2006-26198 US 20070066624 A1 20070222 CA 2006-26198 EP 1924265 A2 20080528 EP 2006-81355 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, BA, HR, MK, RS  JP 2009504769 T 20090205 JP 2008-5271 IN 2008KN00797 A 20081119 CN 2006-80038 US 2005-708471P WO 2006-US32170 W 20060816	WO 2007022371 WO 2007022371 WO 2007022371 WI: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, UG, US, UZ, VC, VN, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  CA 2619881  US 20070066624 A1 20070222 CA 2006-2619881 US 20070066624 A1 20070222 CA 2006-2619881 US 20070066624 A1 20070222 CA 2006-2619881 US 20070066624 A1 20070222 CA 2006-813506 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, BA, HR, MK, RS  JP 2009504769 T 20090205 JP 2008-527141 IN 2008KN00797 CN 101309690 US 2005-708471P P 20050816 US 2006-80038097	MO 2007022371	WO 2007022371  W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UG, US, UZ, VC, VN, ZA, ZM, ZW  RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, N, TD, TG, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  CA 2619881  A1 20070222  CA 2006-2619881  A1 20070222  CA 2006-2619881  A1 20070222  CA 2006-2619881  A2 20080528  EP 2006-813506  C 2  R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, CF, CG, CI, CM, CM, CM, CM, PL, PT, RO, SE, SI, SK, TR, CF, CG, CI, CM, CM, CM, CM, CM, CM, CM, CM, CM, CM	Wo 2007022371						

AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

```
are claimed. More specifically, the invention relates to modulators of
     chemokine receptor activity, preferably modulators of CCR4 or CCR5. In
     one aspect, these compds. demonstrate protective effects against infection
     of target cells by a human immunodeficiency virus (HIV). Example compound
     II was prepared by cross-coupling of 5-bromopyrimidine with
     4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde
     underwent reductive amination with
     (R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give
     compound II. All the invention compds. were evaluated for their chemokine
     receptor binding affinity (data given).
ΙT
     926637-55-0P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate and intermediate; preparation of substituted
        imidazolidinones and related compds. as chemokine receptor binding
        modulators with protective effects against infection of target cells by
        human immunodeficiency virus)
RN
     926637-55-0 CAPLUS
     926637-54-9P 926637-84-5P 926637-85-6P
ΙT
     926637-86-7P 926638-32-6P 926638-33-7P
     926639-19-2P 926639-48-7P 926639-51-2P
     926639-52-3P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (drug candidate; preparation of substituted imidazolidinones and related
        compds. as chemokine receptor binding modulators with protective
        effects against infection of target cells by human immunodeficiency
       virus)
     926637-54-9 CAPLUS
RN
     926637-84-5 CAPLUS
RN
     926637-85-6 CAPLUS
RN
RN
     926637-86-7 CAPLUS
RN
     926638-32-6 CAPLUS
RN
     926638-33-7 CAPLUS
RN
     926639-19-2 CAPLUS
RN
     926639-48-7 CAPLUS
RN
     926639-51-2 CAPLUS
RN
     926639-52-3 CAPLUS
ΙT
     926642-53-7P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of substituted imidazolidinones and related
        compds. as chemokine receptor binding modulators with protective
        effects against infection of target cells by human immunodeficiency
        virus)
     926642-53-7
RN
```

```
ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
1.6
ΑN
      2005:962224 CAPLUS
DN
      143:266945
      Preparation of pyrimidine derivatives as cannabinoid receptor modulators
ΤI
ΙN
      Eatherton, Andrew John; Giblin, Gerard Martin Paul; Mitchell, William
      Leonard; Naylor, Alan
PA
      Glaxo Group Limited, UK
      PCT Int. Appl., 82 pp.
SO
      CODEN: PIXXD2
DT
      Patent
      English
LA
FAN.CNT 1
      PATENT NO.
                             KIND
                                       DATE
                                                   APPLICATION NO.
                                      -----
                                                    _____
                             ____
                                                    WO 2005-EP1939
      WO 2005080350
                                       20050901
                                                                                 20050221
                              A1
PΙ
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
                CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
          CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
               MR, NE, SN, TD, TG
      EP 1718620
                               A1
                                       20061108
                                                    EP 2005-715508
                                                                                 20050221
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
      JP 2007523207
                                                     JP 2007-500151
                              Τ
                                       20070816
                                                                               20050221
      US 20080261977
                                                     US 2006-597521
                                                                                 20060728
                               Α1
                                       20081023
PRAI GB 2004-3998
                               Α
                                       20040223
      GB 2004-25071
                               Α
                                       20041112
      WO 2005-EP1939
                               W
                                       20050221
      CASREACT 143:266945; MARPAT 143:266945
OS
AΒ
      The title compds. I [Y = (un)substituted Ph; R1 = H, alkyl, cycloalkyl,
      haloalkyl; R2 = (CH2)mR3 (wherein m = 0-1); or NR1R2 = (un)substituted 4-8
      membered non-aromatic heterocyclyl; R3 = H, (un)substituted 4-8 membered
      non-aromatic heterocyclyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.;
      R5 = II (wherein p =0-2; X = CH2, O, S, SO, SO2); R6 = halo,
      (un) substituted alkyl, cycloalkyl, etc.; R7 = OH, alkoxy, etc.; R12 = H,
      alkyl; with the provision], useful in the treatment of diseases,
      particularly pain, which are mediated by the activity of the cannabinoid 2
      receptor, were prepared and formulated. Thus, reductive amination of
      2-(3-chlorophenylamino)-4-cyclopropylpyrimidine-5-carbaldehyde with
      aminocyclobutane afforded 19% III which showed an EC50 of <300 nM and
      efficacy value of >50% at the cloned human cannabinoid CB2 receptor.
      863772-57-0P 863772-58-1P 863772-60-5P
      863772-61-6P 863772-62-7P 863772-63-8P
      863772-64-9P 863772-65-0P 863772-67-2P
      863772-69-4P 863772-71-8P 863772-72-9P
      863772-73-0P 863772-74-1P 863772-76-3P
      863772-78-5P 863772-80-9P 863772-82-1P
      863772-84-3P 863772-85-4P 863772-86-5P
      863772-88-7P 863772-90-1P 863772-92-3P
      863772-94-5P 863772-96-7P 863772-97-8P
      863772-98-9P 863773-00-6P 863773-01-7P
```

863773-03-9P 863773-04-0P 863773-05-1P

```
863773-06-2P 863773-07-3P 863773-09-5P
     863773-11-9P 863773-12-0P 863773-14-2P
     863773-16-4P 863773-18-6P 863773-19-7P
     863773-20-0P 863773-22-2P 863773-24-4P
     863773-26-6P 863773-27-7P 863773-28-8P
     863773-30-2P 863773-32-4P 863773-33-5P
     863773-34-6P 863773-35-7P 863773-37-9P
     863773-38-0P 863773-39-1P 863773-41-5P
     863773-43-7P 863773-45-9P 863773-47-1P
     863773-49-3P 863773-50-6P 863773-51-7P
     863773-53-9P 863773-54-0P 863773-55-1P
     863773-57-3P 863773-59-5P 863773-61-9P
     863773-62-0P 863773-63-1P 863773-64-2P
     863773-66-4P 863773-68-6P 863773-70-0P
     863773-72-2P 863773-74-4P 863773-76-6P
     863773-78-8P 863773-79-9P 863773-81-3P
     863773-82-4P 863773-83-5P 863773-85-7P
     863773-86-8P 863773-87-9P 863773-88-0P
     863773-90-4P 863773-92-6P 863773-94-8P
     863773-95-9P 863773-97-1P 863773-98-2P
     863774-00-9P 863774-01-0P 863774-03-2P
     863774-04-3P 863774-05-4P 863774-06-5P
     863774-07-6P 863774-08-7P 863774-09-8P
     863774-10-1P 863774-11-2P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of pyrimidine derivs. as cannabinoid receptor modulators)
RN
     863772-57-0 CAPLUS
RN
     863772-58-1 CAPLUS
RN
     863772-60-5 CAPLUS
RN
     863772-61-6 CAPLUS
RN
     863772-62-7 CAPLUS
RN
     863772-63-8 CAPLUS
RN
     863772-64-9 CAPLUS
RN
     863772-65-0 CAPLUS
RN
     863772-67-2 CAPLUS
RN
     863772-69-4 CAPLUS
RN
     863772-71-8 CAPLUS
RN
     863772-72-9 CAPLUS
RN
     863772-73-0 CAPLUS
     863772-74-1 CAPLUS
RN
     863772-76-3 CAPLUS
RN
     863772-78-5 CAPLUS
RN
     863772-80-9 CAPLUS
RN
     863772-82-1 CAPLUS
RN
RN
     863772-84-3
                 CAPLUS
RN
     863772-85-4
                 CAPLUS
RN
     863772-86-5
                  CAPLUS
RN
     863772-88-7
                  CAPLUS
RN
     863772-90-1
                  CAPLUS
RN
     863772-92-3
                  CAPLUS
RN
     863772-94-5
                 CAPLUS
RN
     863772-96-7
                 CAPLUS
     863772-97-8 CAPLUS
RN
RN
     863772-98-9 CAPLUS
```

DAT	062333 00 6	07.01.110
RN	863773-00-6	CAPLUS
RN	863773-01-7	CAPLUS
RN	863773-03-9	CAPLUS
RN	863773-04-0	CAPLUS
RN	863773-05-1	CAPLUS
RN	863773-06-2	CAPLUS
RN	863773-07-3	CAPLUS
RN	863773-09-5	CAPLUS
RN	863773-11-9	CAPLUS
RN	863773-12-0	CAPLUS
RN	863773-14-2	CAPLUS
RN	863773-16-4	CAPLUS
RN	863773-18-6	
		CAPLUS
RN	863773-19-7	CAPLUS
RN	863773-20-0	CAPLUS
RN	863773-22-2	CAPLUS
RN	863773-24-4	CAPLUS
RN	863773-26-6	CAPLUS
RN	863773-27-7	CAPLUS
RN	863773-28-8	CAPLUS
RN	863773-30-2	CAPLUS
RN	863773-32-4	CAPLUS
RN	863773-33-5	CAPLUS
RN	863773-34-6	CAPLUS
RN	863773-35-7	CAPLUS
RN	863773-37-9	CAPLUS
	863773-38-0	
RN		CAPLUS
RN	863773-39-1	CAPLUS
RN	863773-41-5	CAPLUS
RN	863773-43-7	
		CAPLUS
RN	863773-45-9	CAPLUS
RN	863773-47-1	CAPLUS
RN	863773-49-3	CAPLUS
RN	863773-50-6	CAPLUS
RN	863773-51-7	CAPLUS
RN	863773-53-9	CAPLUS
RN	863773-54-0	CAPLUS
RN	863773-55-1	CAPLUS
RN	863773-57-3	CAPLUS
RN	863773-59-5	CAPLUS
RN	863773-61-9	CAPLUS
RN	863773-62-0	CAPLUS
RN	863773-63-1	CAPLUS
RN	863773-64-2	CAPLUS
	063773-04-2	
RN	863773-66-4	CAPLUS
RN	863773-68-6	CAPLUS
RN	863773-70-0	CAPLUS
RN	863773-72-2	CAPLUS
RN	863773-74-4	CAPLUS
RN	863773-76-6	CAPLUS
	863773-78-8	
RN	003/13-10-8	CAPLUS
RN	863773-79-9	CAPLUS
RN	863773-81-3	CAPLUS
RN	863773-82-4	CAPLUS
RN	863773-83-5	CAPLUS
RN	863773-85-7	CAPLUS
RN	863773-86-8	CAPLUS

```
RN
    863773-87-9 CAPLUS
RN
   863773-88-0 CAPLUS
RN
   863773-90-4 CAPLUS
RN
   863773-92-6 CAPLUS
RN
    863773-94-8 CAPLUS
    863773-95-9 CAPLUS
RN
RN
    863773-97-1 CAPLUS
RN
     863773-98-2 CAPLUS
RN
     863774-00-9 CAPLUS
RN
    863774-01-0 CAPLUS
RN
    863774-03-2 CAPLUS
    863774-04-3 CAPLUS
RN
    863774-05-4 CAPLUS
RN
    863774-06-5 CAPLUS
RN
    863774-07-6 CAPLUS
RN
    863774-08-7 CAPLUS
RN
    863774-09-8 CAPLUS
RN
    863774-10-1 CAPLUS
RN
RN
     863774-11-2 CAPLUS
ΙT
     863774-25-8P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of pyrimidine derivs. as cannabinoid receptor modulators)
RN
     863774-25-8
RE.CNT 3
             THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

=> => d 16 1-2 bib, ab, hitstr

- ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN L6
- 2007:201033 CAPLUS ΑN
- 146:274347 DN
- Substituted imidazolidinones and related compounds as chemokine receptor ΤI binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
- Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, ΙN Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
- PΑ Anormed Inc., Can.
- SO PCT Int. Appl., 363pp. CODEN: PIXXD2
- DT Patent
- English LA

FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE																			
	PATENT NO.							DATE		APPLICATION NO.							DATE		
PI	WO	2007	A2		20070222 20071101						20060816								
			CN, GE, KR, MW, RU, UG, AT, IS, CF,	CO, GH, KZ, MX, SC, US, BE, IT, CG,	CR, GM, LA, MY, SD, UZ, BG, LT, CI,	CU, HN, LC, MZ, SE, VC, CH, LU, CM,	CZ, HR, LK, NA, SG, VN, CY, LV, GA,	AU, DE, HU, LR, NG, SK, ZA, CZ, MC, GN,	DK, ID, LS, NI, SL, ZM, DE, NL, GQ,	DM, IL, LT, NO, SM, ZW DK, PL, GW,	DZ, IN, LU, NZ, SY, EE, PT, ML,	EC, IS, LV, OM, TJ, ES, RO, MR,	EE, JP, LY, PG, TM, FI, SE, NE,	EG, KE, MA, PH, TN, FR, SI, SN,	ES, KG, MD, PL, TR, GB, SK, TD,	FI, KM, MG, PT, TT, GR, TR,	GB, KN, MK, RO, TZ, HU, BF, BW,	GD, KP, MN, RS, UA, IE, BJ, GH,	
			KG,	KΖ,	MD,	RU,	ТJ,	NA, TM,	AP,	EA,	EP,	ΟA							
														20060816					
						A1 2007032													
	ΕP	1924	265			A2 2008			0528		EP 2	006-	813506			20060816			
		R:	AT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
			•	IT, HR,	•		LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	AL,	
	JΡ	2009	5047	69 <sup>.</sup>	·	Τ		2009	0205	JP 2008-527141			41		20060816				
	IN					Α		2008	1121	IN 2008-KN797						20080222			
PRAI	US	1013 2005	-708	471P		P		2005	0816										
		2006																	
OS	MAI	RPAT	146:	2743	47														

The invention relates to chemokine receptor binding compds. of formula I, AB pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un) substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un) substituted (hetero) aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un) substituted alkenyl, (un) substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with

(R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926637-55-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Page 14

- L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
- AN 2007:201033 CAPLUS
- DN 146:274347
- TI Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus
- IN Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig, Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
- PA Anormed Inc., Can.
- SO PCT Int. Appl., 363pp. CODEN: PIXXD2
- DT Patent
- LA English

FAN.CNT 1

FAN.	FAN.CNT 1 PATENT NO.						KIND DATE				APPL	ICAT		DATE					
PI		2007 2007	A2					WO 2	006-		20060816								
			AE, CN, GE, KR, MW,	AG, CO, GH, KZ, MX,	AL, CR, GM, LA, MY,	AM, CU, HN, LC, MZ,	AT, CZ, HR, LK, NA,	AU, DE, HU, LR, NG,	AZ, DK, ID, LS, NI,	DM, IL, LT, NO,	DZ, IN, LU, NZ,	EC, IS, LV, OM,	EE, JP, LY, PG,	EG, KE, MA, PH,	ES, KG, MD, PL,	FI, KM, MG, PT,	GB, KN, MK, RO,	GD, KP, MN, RS,	
		RU, SC, SI UG, US, U		UZ,	VC,	VN,	ZA,	ZM,	ZW		,	,	,	•	,	•	·		
		KW:	IS, CF,	IT, CG,	LT, CI,	LU, CM,	LV, GA,	CZ, MC, GN, NA,	NL, GQ,	PL, GW,	PT, ML,	RO, MR,	SE, NE,	SI, SN,	SK, TD,	TR, TG,	BF, BW,	BJ, GH,	
	~ 7	2610					•	TM,	•	,			2610	0 0 1		2.	0060	016	
														20060816 20060816					
									EP 2006-813506										
		R:	IS,		LI,	LT,		CZ, LV,											
	JP	2009	•	•				2009	0205		JP 2008-527141					20060816			
		2009504769 2008KN00797								IN 2008-KN797									
PRAI	US	1013 2005 2006	-708	471P		P			0816		CN 2	006-	8003	8097		20	080	414	
OS	WO 2006-US32170 W 20060816 MARPAT 146:274347																		

AB The invention relates to chemokine receptor binding compds. of formula I, pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un)substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un)substituted (hetero)aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with

(R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

COMMAND INTERRUPTED
REENTER FILE 'CAPLUS'
AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

Your command did not complete due to a temporary system problem. To recover, reenter the file you are in now. Then, any command that is normally available to you may be used. No cost summary for the current file will be displayed. After reentering the current file you may retry your command. Also, you may wish to SAVE your search query. This can be done in any file. If you cannot access your current file, or if your command fails a second time, notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or by using the SEND command in STNMAIL file.

=> d 16 1-2 bib, ab, hitstr
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> => d 16 1-2 bib, ab, hitstr IT 926637-55-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

```
ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
L6
     2007:201033 CAPLUS
ΑN
     146:274347
DN
     Substituted imidazolidinones and related compounds as chemokine receptor
ΤI
     binding compounds and their preparation, pharmaceutical compositions and
     use in the treatment of infection of target cells by human
     immunodeficiency virus
     Zhou, Yuanxi; Bourque, Elyse; Zhu, Yongbao; McEachern, Ernest J.; Harwig,
ΙN
     Curtis; Skerlj, Renato T.; Bridger, Gary J.; Li, Tong-Shuang; Metz, Markus
PA
     Anormed Inc., Can.
SO
     PCT Int. Appl., 363pp.
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
                                   DATE
     PATENT NO.
                           KIND
                                                APPLICATION NO.
                                                                          DATE
                           ____
                                                _____
     WO 2007022371
                            A2
                                   20070222
                                                WO 2006-US32170
                                                                          20060816
ΡI
     WO 2007022371
                            AЗ
                                   20071101
         W: AE, AG, AL, AM, AT, AU, AZ, ABA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
              MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
              RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA,
              UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
              CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
              GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
                                                CA 2006-2619881
     CA 2619881
                            Α1
                                   20070222
                                                                          20060816
     US 20070066624
                            A1
                                   20070322
                                                US 2006-505669
                                                                          20060816
     EP 1924265
                            Α2
                                   20080528
                                                EP 2006-813506
                                                                          20060816
```

MARPAT 146:274347 OS The invention relates to chemokine receptor binding compds. of formula I, AΒ pharmaceutical compns. and their use. Compds. of formula I wherein V and W are independently N and CR; X is O, S, NH and derivs., NOH and derivs., N-acyl, etc.; Y is O, S, N and CR; Z is absent, (un) substituted alkyl, OH and derivs., CO2H and derivs., CONH2 and derivs., carbocycle, heterocycle, and (hetero)aryl; Ar is (un)substituted carbocycle, (un)substituted heterocycle, and (un) substituted (hetero) aryl; L is absent id Z is absent; L is linker between Ar and Z, wherein L is a bond, O, S, NH and derivs., SO, SO2, SO2NH and derivs., co, etc.; R2 is (un)substituted alkyl, (un) substituted alkenyl, (un) substituted alkynyl, carbocycle, heterocycle, and (hetero)aryl; R3 is absent when Y is O and S; when Y is N or CR, R3 is H, NH2 and derivs., CONHOH and derivs., CONH2 and derivs., acyl, CO2H and derivs., OH and derivs., etc.; each R and R4 are independently H and C1-6 alkyl; n is 1 - 3; and their pharmaceutically acceptable salts thereof,

20090205

20084121

20081119

20050816

20060816

BA, HR, MK, RS

Τ

Α

Α

Ρ

W

JP 2009504769

CN 101309690

PRAI US 2005-708471P

IN 2008KN00797

WO 2006-US32170

AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,

JP 2008-527141

CN 2006-80038097

IN 2008-KN797

20060816

20080222

20080414

are claimed. More specifically, the invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compds. demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Example compound II was prepared by cross-coupling of 5-bromopyrimidine with 4-formylbenzeneboronic acid; the resulting 4-(pyrimidin-5-yl)benzaldehyde underwent reductive amination with

(R)-1-cyclohexyl-4-phenyl-3-(piperidin-4-yl)imidazolidin-2-one to give compound II. All the invention compds. were evaluated for their chemokine receptor binding affinity (data given).

IT 926637-55-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-55-0 CAPLUS

CN Benzoic acid, 4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]-(CA INDEX NAME)

Absolute stereochemistry.

IT 926637-54-9P 926637-84-5P 926637-85-6P 926637-86-7P 926638-32-6P 926638-33-7P 926639-19-2P 926639-48-7P 926639-51-2P 926639-52-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926637-54-9 CAPLUS

CN Benzoic acid, 4-[[5-[[4-[(5R)-3-cyclohexyl-2-oxo-5-phenyl-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 926637-84-5 CAPLUS

CN Benzamide, N-cyclopropyl-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 926637-85-6 CAPLUS

CN Benzamide, N-methoxy-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

RN 926637-86-7 CAPLUS

CN Benzamide, N-(1-methylethyl)-4-[[4-methyl-5-[[4-[(5R)-2-oxo-5-phenyl-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 926638-32-6 CAPLUS

CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(3-chloropheny1)-2-oxo-3-(tetrahydro-2H-pyran-4-y1)-1-imidazolidiny1]-1-piperidiny1]methy1]-4-methy1-2-pyrimidiny1]amino]- (CA INDEX NAME)

- RN 926638-33-7 CAPLUS
- CN Benzoic acid, 4-[[5-[[4-[5-(3-chlorophenyl)-3-cyclohexyl-2-oxo-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 926639-19-2 CAPLUS

CN Methanesulfonamide, N-[4-[[4-methyl-5-[[4-[(4R)-2-oxo-4-phenyl-3-oxazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 926639-48-7 CAPLUS

CN Benzoic acid, 4-[[4-methyl-5-[[4-[(5R)-5-(3-methylphenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

RN 926639-51-2 CAPLUS

CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(2-fluoro-5-methylphenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 926639-52-3 CAPLUS

CN Benzoic acid, 4-[[5-[[4-[(5R)-5-(3-fluorophenyl)-2-oxo-3-(tetrahydro-2H-pyran-4-yl)-1-imidazolidinyl]-1-piperidinyl]methyl]-4-methyl-2-pyrimidinyl]amino]- (CA INDEX NAME)

IT 926642-53-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted imidazolidinones and related compds. as chemokine receptor binding modulators with protective effects against infection of target cells by human immunodeficiency virus)

RN 926642-53-7 CAPLUS

CN 2-Oxazolidinone, 3-[1-[[2-[(4-aminophenyl)amino]-4-methyl-5-pyrimidinyl]methyl]-4-piperidinyl]-4-phenyl-, (4R)- (CA INDEX NAME)

```
ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
L6
      2005:962224 CAPLUS
ΑN
DN
      143:266945
      Preparation of pyrimidine derivatives as cannabinoid receptor modulators
ΤI
ΙN
      Eatherton, Andrew John; Giblin, Gerard Martin Paul; Mitchell, William
      Leonard; Naylor, Alan
PA
      Glaxo Group Limited, UK
      PCT Int. Appl., 82 pp.
SO
      CODEN: PIXXD2
                                                             Applicant's
DT
      Patent
      English
LA
FAN.CNT 1
      PATENT NO.
                             KIND
                                       DATE
                                                    APPLICATION NO.
                                       _____
                                                     _____
                              ____
      WO 2005080350
                                       20050901
                                                     WO 2005-EP1939
                               A1
                                                                                  20050221
PΙ
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
                CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
          CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
               MR, NE, SN, TD, TG
      EP 1718620
                               A1
                                       20061108
                                                     EP 2005-715508
                                                                                  20050221
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
      JP 2007523207
                               Τ
                                       20070816
                                                     JP....2007-500151
                                                                                  20050221
      US 20080261977
                                       20081023 US 2006-597521
                                                                                  20060728
                               Α1
PRAI GB 2004-3998
                               Α
                                       20040223
      GB 2004-25071
                                       20041112
                               Α
      WO 2005-EP1939
                               W
                                       20050221
      CASREACT 143:266945; MARPAT 143:266945
OS
AΒ
      The title compds. I [Y = (un)substituted Ph; R1 = H, alkyl, cycloalkyl,
      haloalkyl; R2 = (CH2)mR3 (wherein m = 0-1); or NR1R2 = (un)substituted 4-8
      membered non-aromatic heterocyclyl; R3 = H, (un)substituted 4-8 membered
      non-aromatic heterocyclyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, etc.;
      R5 = II (wherein p =0-2; X = CH2, O, S, SO, SO2); R6 = halo,
      (un) substituted alkyl, cycloalkyl, etc.; R7 = OH, alkoxy, etc.; R12 = H,
      alkyl; with the provision], useful in the treatment of diseases,
      particularly pain, which are mediated by the activity of the cannabinoid 2
      receptor, were prepared and formulated. Thus, reductive amination of
      2-(3-chlorophenylamino)-4-cyclopropylpyrimidine-5-carbaldehyde with
      aminocyclobutane afforded 19% III which showed an EC50 of <300 nM and
      efficacy value of >50% at the cloned human cannabinoid CB2 receptor.
      863772-57-0P 863772-58-1P 863772-60-5P
      863772-61-6P 863772-62-7P 863772-63-8P
      863772-64-9P 863772-65-0P 863772-67-2P
      863772-69-4P 863772-71-8P 863772-72-9P
      863772-73-0P 863772-74-1P 863772-76-3P
      863772-78-5P 863772-80-9P 863772-82-1P
      863772-84-3P 863772-85-4P 863772-86-5P
      863772-88-7P 863772-90-1P 863772-92-3P
      863772-94-5P 863772-96-7P 863772-97-8P
      863772-98-9P 863773-00-6P 863773-01-7P
```

```
863773-03-9P 863773-04-0P 863773-05-1P
863773-06-2P 863773-07-3P 863773-09-5P
863773-11-9P 863773-12-0P 863773-14-2P
863773-16-4P 863773-18-6P 863773-19-7P
863773-20-0P 863773-22-2P 863773-24-4P
863773-26-6P 863773-27-7P 863773-28-8P
863773-30-2P 863773-32-4P 863773-33-5P
863773-34-6P 863773-35-7P 863773-37-9P
863773-38-0P 863773-39-1P 863773-41-5P
863773-43-7P 863773-45-9P 863773-47-1P
863773-49-3P 863773-50-6P 863773-51-7P
863773-53-9P 863773-54-0P 863773-55-1P
863773-57-3P 863773-59-5P 863773-61-9P
863773-62-0P 863773-63-1P 863773-64-2P
863773-66-4P 863773-68-6P 863773-70-0P
863773-72-2P 863773-74-4P 863773-76-6P
863773-78-8P 863773-79-9P 863773-81-3P
863773-82-4P 863773-83-5P 863773-85-7P
863773-86-8P 863773-87-9P 863773-88-0P
863773-90-4P 863773-92-6P 863773-94-8P
863773-95-9P 863773-97-1P 863773-98-2P
863774-00-9P 863774-01-0P 863774-03-2P
863774-04-3P 863774-05-4P 863774-06-5P
863774-07-6P 863774-08-7P 863774-09-8P
863774-10-1P 863774-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of pyrimidine derivs. as cannabinoid receptor modulators)
863772-57-0 CAPLUS
5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-
cyclopropyl- (CA INDEX NAME)
```

RN

CN

RN 863772-58-1 CAPLUS
CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopropyl-4-(1-methylethyl)- (CA INDEX NAME)

RN 863772-60-5 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-cyclopropyl-N-(cyclopropylmethyl)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 863772-59-2 CMF C18 H21 C1 N4

CM 2

CRN 64-19-7 CMF C2 H4 O2

RN 863772-61-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-cyclopropyl-5-(4-morpholinylmethyl)- (CA INDEX NAME)

RN 863772-62-7 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-cyclopropyl-N-(2-methylpropyl)- (CA INDEX NAME)

RN 863772-63-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1-methylethyl)-5-(4-morpholinylmethyl)- (CA INDEX NAME)

RN 863772-64-9 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclopropylmethyl)-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

## ● HCl

RN 863772-65-0 CAPLUS

CN 5-Pyrimidine methanamine, 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

## ● HCl

RN

863772-67-2 CAPLUS Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methoxyethyl)-4-(1-  $(1-1)^{-1}$ CN methylethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-66-1 C17 H23 C1 N4 O CMF

СМ 2

CRN 64-18-6 CMF C H2 O2

О== СН-ОН

RN 863772-69-4 CAPLUS

Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-4-CN (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-68-3 CMF C18 H20 C1 F3 N4

CH2-NH-CH2 ΝН F3C

> СМ 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

863772-71-8 CAPLUS
Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methylpropyl)-4-CN (trifluoromethy1)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-70-7 CMF C16 H18 C1 F3 N4

i-BuNH-CH2

СМ 2

CRN 64-18-6 CMF C H2 O2

O CH OH

863772-72-9 CAPLUS RN

5- Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclohexylmethyl)-4-CN (trifluoromethyl) - (CA INDEX NAME)

RN 863772-73-0 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chloro-4-fluorophenyl)amino]-N- (cyclopropylmethyl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

HC1

RN 863772-74-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863772-76-3 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-y1)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-75-2

CMF C18 H20 C1 F3 N4 O

CM 2

CRN 64-18-6 CMF C H2 O2

О == СН − ОН

RN 863772-78-5 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(tetrahydro-2H-pyran-4-yl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-77-4

CMF C17 H18 C1 F3 N4 O

CM 2

CRN 64-18-6 CMF C H2 O2

RN 863772-80-9 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-methoxyethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-79-6

CMF C15 H16 C1 F3 N4 O

CM 2

CRN 64-18-6 CMF C H2 O2

O== CH-OH

RN 863772-82-1 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclobutylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-81-0 CMF C17 H18 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863772-84-3 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-propyl-4- (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-83-2 CMF C15 H16 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2 O = CH - OH

RN 863772-85-4 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(2,2-dimethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)

Me<sub>3</sub>C-CH<sub>2</sub>-NH-CH<sub>2</sub>
N
NH
NH

RN 863772-86-5 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-(trifluoromethyl)- (CA INDEX NAME)

NH-CH<sub>2</sub> N NH

RN 863772-88-7 CAPLUS

CN Formic acid, compd. with N-butyl-2-[(3-chlorophenyl)amino]-4- (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-87-6

CMF C16 H18 C1 F3 N4

n-BuNH-CH2

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН-ОН

RN 863772-90-1 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-cyclopropyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CRN 863772-89-8 CMF C15 H14 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

о== сн− он

863772-92-3 CAPLUS

CN Formic acid, compd. with 2-[(3-chloropheny1)amino]-N-(3-methylbutyl)-4-(trifluoromethy1)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM

CRN 863772-91-2 CMF C17 H20 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

RN

863772-94-5 CAPLUS
Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopropylmethyl)-4-(trifluoromethy1)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1 CRN 863772-93-4 CMF C16 H16 C1 F3 N4

СМ 2

CRN 64-18-6 C H2 O2 CMF

O = CH - OH

RN

863772-96-7 CAPLUS
Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(tetrahydro-1,1-CN dioxido-2H-thiopyran-4-yl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

СМ

CRN 863772-95-6

C17 H18 C1 F3 N4 O2 S CMF

CM 2

64-18-6 CRN C H2 O2 CMF

O = CH - OH

863772-97-8 CAPLUS RN

5- Pyrimidine methan a mine, 2- [(2,4-dichlorophenyl) a mino] - N- (2-methyl propyl) - (2-methyl propyl) - (3-methyl propyl)CN 4-(trifluoromethyl)- (CA INDEX NAME)

RN 863772-98-9 CAPLUS

CN 5-Pyrimidinemethanamine, N-(cyclopropylmethyl)-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-00-6 CAPLUS

CN Formic acid, compd. with N-(cyclobutylmethyl)-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863772-99-0

CMF C17 H17 C12 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-01-7 CAPLUS

CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-03-9 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-02-8 CMF C18 H15 C1 F3 N5

CM 2

CRN 64-18-6 CMF C H2 O2

О=== СН-- ОН

RN 863773-04-0 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-N-(2,2-dimethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-05-1 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]-N-(2-methoxyethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-06-2 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopentyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-07-3 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-09-5 CAPLUS

CN Formic acid, compd. with 2-[(3-fluorophenyl)amino]-N-(2-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-08-4 CMF C16 H18 F4 N4

CM 2

CRN 64-18-6 CMF C H2 O2 O = CH - OH

RN 863773-11-9 CAPLUS

CN Formic acid, compd. with N-(cyclobutylmethyl)-2-[(3-fluorophenyl)amino]-4- (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-10-8 CMF C17 H18 F4 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

RN 863773-12-0 CAPLUS

CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-14-2 CAPLUS

CN Formic acid, compd. with N-(3-chlorophenyl)-5-(1-piperidinylmethyl)-4- (trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-13-1 CMF C17 H18 C1 F3 N4

CM2 CRN 64-18-6 CMF C H2 O2 О== СН-ОН RN 863773-16-4 CAPLUS CN Formic acid, compd. with N-(3-chlorophenyl)-5-(1-pyrrolidinylmethyl)-4-(trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME) CM1 CRN 863773-15-3 CMF C16 H16 C1 F3 N4 CH<sub>2</sub> CM 2 CRN 64-18-6 CMF C H2 O2 O = CH - OH863773-18-6 CAPLUS RNFormic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(4-CN fluorophenyl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

СМ

1

CRN 863773-17-5

CMF C19 H15 C1 F4 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

RN 863773-19-7 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me} & & & \\ \hline \text{CH}_2 - \text{N} - \text{CH}_2 & & \text{N} \\ \hline \\ \text{F}_3 \text{C} & & \text{N} \end{array}$$

RN 863773-20-0 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclohexyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-22-2 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N,N-dimethyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-21-1

CMF C14 H14 C1 F3 N4

CRN 64-18-6 CMF C H2 O2

О== СН−ОН

RN 863773-24-4 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-phenylethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-23-3 CMF C20 H18 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-26-6 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl) amino]-N-(3-phenylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-25-5 CMF C21 H20 C1 F3 N4

CRN 64-18-6 CMF C H2 O2

O CH OH

RN 863773-27-7 CAPLUS

CN 5-Pyrimidinemethanamine, N-butyl-2-[(3-chlorophenyl)amino]-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-28-8 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(1-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 1006606-92-3 CMF C16 H18 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2 О СН ОН

RN 863773-30-2 CAPLUS


CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[[(2R)-tetrahydro-2-furanyl]methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-29-9

CMF C17 H18 C1 F3 N4 O

Absolute stereochemistry.



CM 2

CRN 64-18-6 CMF C H2 O2

o = CH - OH

RN 863773-32-4 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[[(2S)-tetrahydro-2-furanyl]methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-31-3

CMF C17 H18 C1 F3 N4 O

Absolute stereochemistry.

CM 2

CRN 64-18-6 CMF C H2 O2

O=== CH-- OH

RN 863773-33-5 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(cyclobutylmethyl)-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-34-6 CAPLUS

CN 2-Propanol, 1-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]- (CA INDEX NAME)

RN 863773-35-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-dichlorophenyl)-5-(1-pyrrolidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN

863773-37-9 CAPLUS
Formic acid, compd. with N-(cyclopropylmethyl)-2-[(3-fluorophenyl)amino]-4-CN (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM

CRN 863773-36-8 CMF C16 H16 F4 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

863773-38-0 CAPLUS RN

5-Pyrimidinemethanamine, 2-[(3-fluorophenyl)amino]-N-(3-methylbutyl)-4-(trifluoromethyl)- (CA INDEX NAME) CN

Me<sub>2</sub>CH-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>

863773-39-1 CAPLUS RN

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-5-(4-morpholinylmethyl)-4-(trifluoromethyl) - (CA INDEX NAME)

CH<sub>2</sub> NH F<sub>3</sub>C

RN

863773-41-5 CAPLUS Formic acid, compd. with N-(2,2-dimethylpropyl)-2-[(3-fluorophenyl)amino]-  $\frac{1}{2}$ CN 4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM

CRN 863773-40-4 CMF C17 H20 F4 N4

 $Me_3C-CH_2-NH-CH_2$ 

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-43-7 CAPLUS

Formic acid, compd. with 3-[[5-[(cyclopropylamino)methyl]-4-CN (trifluoromethy1)-2-pyrimidiny1]amino]benzonitrile (1:1) (CA INDEX NAME)

1 CM

863773-42-6 CRN CMF C16 H14 F3 N5

CRN 64-18-6 CMF C H2 O2

О== СН−ОН

RN

863773-45-9 CAPLUS Formic acid, compd. with 3-[[5-[[(2-methylpropyl)amino]methyl]-4-[]CN (trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM

CRN 863773-44-8 CMF C17 H18 F3 N5

CM2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-47-1 CAPLUS

Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-cyclohexyl-N-methyl-4-CN (trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-46-0 CMF C19 H22 C1 F3 N4

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN

863773-49-3 CAPLUS Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-methyl-N-  $\,$ CN (phenylmethyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM

CRN 863773-48-2 CMF C20 H18 C1 F3 N4

$$\begin{array}{c} \text{Me} \\ \text{Ph-CH}_2 - \text{N-CH}_2 \\ \\ \text{F3C} \end{array} \qquad \begin{array}{c} \text{N} \\ \text{N} \end{array}$$

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

863773-50-6 CAPLUS RN

5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N,N-dipropyl-4-(trifluoromethyl)- (CA INDEX NAME) CN

RN 863773-51-7 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(1-methylethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-53-9 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(1-methyl-4-piperidinyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-52-8 CMF C18 H21 C1 F3 N5

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

RN 863773-54-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 863773-55-1 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(4-piperidinylmethyl)-4-(trifluoromethyl)-, hydrochloride (1:2) (CA INDEX NAME)

●2 HC1

RN 863773-57-3 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(2-ethylbutyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-56-2 CMF C18 H22 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-59-5 CAPLUS

CN Formic acid, compd. with N2-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-N1,N1-dimethyl-1,2-ethanediamine (1:1) (CA INDEX NAME)

CRN 863773-58-4

CMF C16 H19 C1 F3 N5

CM 2

CRN 64-18-6 CMF C H2 O2

o = CH - OH

RN 863773-61-9 CAPLUS

CN Formic acid, compd. with N3-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-N1,N1-dimethyl-1,3-propanediamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-60-8

CMF C17 H21 C1 F3 N5

$$Me_2N-(CH_2)_3-NH-CH_2$$
 $F_3C$ 
 $N$ 
 $NH$ 

CM 2

CRN 64-18-6

CMF C H2 O2

О== СН−ОН

RN 863773-62-0 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-63-1 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(1-ethylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-64-2 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-(3,3-dimethylbutyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-66-4 CAPLUS

CN Formic acid, compd. with 1-[[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]methyl]cyclohexanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-65-3 CMF C19 H22 C1 F3 N4 O

CM 2

CRN 64-18-6 CMF C H2 O2

O== CH-OH

RN 863773-68-6 CAPLUS

CN Formic acid, compd. with 2-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]ethanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-67-5

CMF C14 H14 C1 F3 N4 O

HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>

F<sub>3</sub>C

N

NH

C<sub>1</sub>

CM 2

CRN 64-18-6 CMF C H2 O2

o = ch - oh

RN 863773-70-0 CAPLUS

CN Formic acid, compd. with N-[2-[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]amino]ethyl]acetamide (1:1) (CA INDEX NAME)

CM 1

CRN 863773-69-7

CMF C16 H17 C1 F3 N5 O

AcNH-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>

F<sub>3</sub>C

N

NH

CJ

CM 2

CRN 64-18-6

CMF C H2 O2

O = CH - OH

RN 863773-72-2 CAPLUS

CN Formic acid, compd. with 2-[(3-fluorophenyl)amino]-N-(1-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-71-1 CMF C16 H18 F4 N4

Me Et-CH-NH-CH<sub>2</sub> F<sub>3</sub>C N NH

CM 2

CRN 64-18-6 CMF C H2 O2

o = CH - OH

RN 863773-74-4 CAPLUS

CN Formic acid, compd. with 3-[[5-(4-morpholinylmethyl)-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-73-3 CMF C17 H16 F3 N5 O

CM 2

CRN 64-18-6 CMF C H2 O2 O = CH - OH

RN 863773-76-6 CAPLUS

CN Formic acid, compd. with 3-[[5-[[(cyclopropylmethyl)amino]methyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]benzonitrile (1:1) (CA INDEX NAME)

CM 1

CRN 863773-75-5 CMF C17 H16 F3 N5

CM 2

CRN 64-18-6 CMF C H2 O2

о== сн−он

RN 863773-78-8 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)] = N-[(6-methoxy-3-pyridinyl)] = 4-(trifluoromethyl) = 5-pyrimidinemethanamine (CA INDEX NAME)

CM 1

CRN 863773-77-7

CMF C19 H17 C1 F3 N5 O

MeO 
$$_{\rm N}$$
  $_{\rm CH_2-NH-CH_2}$   $_{\rm N}$   $_{\rm NH}$   $_{\rm C1}$ 

CM 2

CRN 64-18-6 CMF C H2 O2 O = CH - OH

RN 863773-79-9 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-(CA INDEX NAME)

H<sub>2</sub>N-CH<sub>2</sub> N NH Cl

RN 863773-81-3 CAPLUS

CN Formic acid, compd. with N-(3-chlorophenyl)-5-[(4-methyl-1-piperazinyl)methyl]-4-(trifluoromethyl)-2-pyrimidinamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-80-2 CMF C17 H19 C1 F3 N5

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-82-4 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-[1-(4-fluorophenyl)ethyl]-4-(trifluoromethyl)- (CA INDEX NAME)

$$\begin{array}{c|c} F & Me \\ \hline CH-NH-CH_2 & N \\ \hline F_3C & N \end{array}$$

RN 863773-83-5 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N,N-bis(2-methoxyethyl)-4-(trifluoromethyl)- (CA INDEX NAME)

$$\begin{array}{c|c} \text{MeO-CH}_2\text{-CH}_2\\ \text{MeO-CH}_2\text{-CH}_2\text{-N-CH}_2\\ \end{array}$$

RN 863773-85-7 CAPLUS

CN Formic acid, compd. with 1-[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]methyl]-4-piperidinemethanol (1:1) (CA INDEX NAME)

CM 1

CRN 863773-84-6

CMF C18 H20 C1 F3 N4 O

$$N$$
  $CH_2$   $N$   $NH$   $CH$ 

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-86-8 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclopropyl- $\alpha$ -methyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-87-9 CAPLUS

CN 5-Pyrimidinemethanamine, N-cyclopropyl-2-[(3-fluorophenyl)amino]- $\alpha$ -methyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-88-0 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-fluorophenyl)amino]- $\alpha$ -methyl-N-(2-methylpropyl)-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-90-4 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]- $\alpha$ -methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-89-1

CMF C19 H22 C1 F3 N4 O

$$\begin{array}{c|c} & \text{Me} \\ \hline \\ \text{CH}_2 - \text{NH} - \text{CH} \\ \hline \\ \text{F}_3\text{C} \\ \end{array} \begin{array}{c} \text{N} \\ \\ \text{NH} \\ \end{array} \begin{array}{c} \text{C1} \\ \end{array}$$

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-92-6 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclohexylmethyl)-  $\alpha$ -methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CRN 863773-91-5

CMF C20 H24 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

o = CH - OH

RN 863773-94-8 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-(cyclopentylmethyl)-  $\alpha$ -methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-93-7

CMF C19 H22 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН− ОН

RN 863773-95-9 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(2,4-dichlorophenyl)amino]- $\alpha$ -methyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863773-97-1 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]- $\alpha$ -methyl-N-(2-methylpropyl)-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-96-0 CMF C17 H20 C1 F3 N4

CM 2

CRN 64-18-6 CMF C H2 O2

O = CH - OH

RN 863773-98-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-5-[1-(4-morpholinyl)ethyl]-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863774-00-9 CAPLUS

CN Formic acid, compd. with N-(cyclopropylmethyl)-2-[(3-fluorophenyl)amino]-

 $\alpha$ -methyl-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863773-99-3 CMF C17 H18 F4 N4

CM 2

CRN 64-18-6 CMF C H2 O2

О== СН−ОН

RN 863774-01-0 CAPLUS

CN 5-Pyrimidinemethanamine, N-(cyclohexylmethyl)-2-[(2,4-dichlorophenyl)amino]- $\alpha$ -methyl-4-(trifluoromethyl)- (CA INDEX NAME)

RN 863774-03-2 CAPLUS

CN Formic acid, compd. with 2-[(3-chlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)-5-pyrimidinemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 863774-02-1 CMF C18 H14 C1 F4 N5

CRN 64-18-6 CMF C H2 O2

О СН ОН

RN 863774-04-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1,1-dimethylethyl)-5-(4-morpholinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)

## ● HCl

RN 863774-05-4 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-N-cyclobutyl-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

## ● HCl

RN 863774-06-5 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N[(tetrahydro-2H-pyran-4-yl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

● HC1

RN 863774-07-6 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-[(4-fluorophenyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 863774-08-7 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-(2-methoxyethyl)-, hydrochloride (1:1) (CA INDEX NAME)

● HC1

RN 863774-09-8 CAPLUS

CN 5-Pyrimidinemethanamine, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-(2-methylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 863774-10-1 CAPLUS

CN 5-Pyrimidine methan a mine, 2-[(3-chlorophenyl) a mino]-N-(cyclopropyl methyl)-4-(cyclopropyl methyl)-4-(cyclopr(1,1-dimethylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

863774-11-2 CAPLUS RN

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1-methylethyl)-5-(1piperazinylmethyl) -, hydrochloride (1:1) (CA INDEX NAME)

● HCl

863774-25-8P ΙT

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

> (preparation of pyrimidine derivs. as cannabinoid receptor modulators) 863774-25-8 CAPLUS

RN

Carbamic acid, [[2-[(3-chloro-4-fluorophenyl)amino]-4-(trifluoromethyl)-5-CN pyrimidinyl]methyl](cyclopropylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10/597,521

=> log y		
COST	IN U.S.	DOLLARS

SINCE FILE TOTAL ENTRY SESSION 12.28 212.50

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE

-1.64 -3.28

STN INTERNATIONAL LOGOFF AT 18:24:06 ON 26 MAR 2009